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Introduction
A recent meta-analysis by Casas et al. [1] concluded
that ACE inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) reduce the progression of renal
events by nothing more than their blood pressure
(BP)-lowering effect. Surprisingly, this meta-analysis
[1] contradicts most randomized controlled trials and
other meta-analyses [2–5] investigating the effect of
inhibition of the renin–angiotensin system (RAS) on the
progression of chronic kidney disease. We have analysed
the methodological quality of this meta-analysis and
put it into perspective with other meta-analyses and
large randomized controlled trials. We have come to
the conclusion that there are serious problems, which
undermine the conclusion drawn by Casas et al. [1].
Data analysis by Casas et al. [1]
How did the authors reach their surprising conclusion?
Casas et al. [1] selected randomized controlled trials
comparing inhibitors of the RAS with other regimens,
defining the progression of renal disease as doubling
of serum creatinine, end-stage renal disease (ESRD),
change of glomerular filtration rate (GFR), change of
serum creatinine or change of urine albumin. The most
frequently used primary renal outcome, the combina-
tion of doubling of serum creatinine and ESRD,
was not analysed. They found 127 trials, of which
only 20 provided data on ESRD, and 18 on doubling
of serum creatinine. They concluded from these trials
that ACEIs and ARBs are not more renoprotective
than can be explained by lowering of BP in diabetic
kidney disease, while in non-diabetic kidney disease
a BP-independent renoprotective effect is uncertain.
However, even with the inclusion of the neutral data
of Antihypertensive and Lipid Lowering Treatment
to Prevent Heart Attack Trial (ALLHAT), ESRD was
reduced by ACEIs/ARBs by 13% (P¼ 0.04) compared
with other antihypertensive drugs, despite an insignifi-
cant difference in BP compared with the comparator
group (1.3/0.5mmHg) [1]. The ALLHAT effect was
evident when, in a sensitivity analysis, the ALLHAT
data were excluded when calculating a summary study
effect in the meta-analysis: in this instance, there were
statistically significant and clinically important reno-
protective benefits of both large studies (24% reduc-
tion in risk of ESRD) and small studies (32% benefit).
The latter positive findings are in stark contrast
to those observed in the ALLHAT trial, i.e. a 5%
increased risk of ESRD among ACEI-treated patients.
There was a similar reduction of relative risk (RR)
for doubling of serum creatinine by 29% (borderline
significance, P¼ 0.07) when the ALLHAT data were
included in the meta-analysis, despite an insignificant
difference in BP between ACEIs/ARBs and compara-
tor groups (0.9/þ0.2mmHg). Again, there was
another important ALLHAT effect. Among small
studies with fewer than 500 patients (i.e. those
excluding ALLHAT) a statistically significant and
clinically important 45% reduction in risk for doubling
of serum creatinine was noted, while in the three
large studies including ALLHAT, there was only
a 3% reduction in risk [RR 0.97; 95% confidence
interval (CI) 0.49–1.92] in the summary result.
However, the crude rate of doubling serum creatinine
in the intervention group was 8.7% and in the control
group was 12.3% resulting in an RR of 0.7 (using
a naı¨ve calculation). Such a discrepancy between naı¨ve
calculation and pooled summary raises a suspicion
about substantial heterogeneity across trials, which
should probably not be pooled in the first place.
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Similar discrepancies for crude RR and the RR
calculated in a random effects model apply to the six
diabetic trials reporting the doubling of serum creati-
nine [1]. Based on the observations on doubling of
serum creatinine one should conclude, in contrast
to Casas et al. [1], that when compared with placebo
(combined with other antihypertensives) ACEIs/ARBs
reduce the RR for ESRD significantly and that
the preponderance of the evidence supports an
ACEIs/ARBs effect for reduction in the risk of
doubling of serum creatinine.
It should be further noted that Casas et al. [1]
reported a statistically significant renoprotective
benefit of ACEIs/ARBs for the change in serum
creatinine over study time, 7.07mmol/l lower in
ACEIs/ARBs treated subjects, and in urinary albumin
excretion, 15.7mg/day lower in ACEIs/ARBs treated
subjects. In contrast, no benefit for ACEIs/ARBs
was noted concerning the change of creatinine-
based estimates of GFR. The latter is not entirely
unexpected, given the imprecision of creatinine-based
estimates of GFR. The endpoint ‘change of GFR’, was
also strongly blurred by the overwhelming number
of low-risk patients in the ALLHAT study, which did
not collect data on urine albumin. It is highly
likely that ALLHAT removed any effect of change
in GFR in the non-ALLHAT studies. It is of further
note that in diabetic patients, treatment with ACEIs/
ARBs compared with other antihypertensive
drugs reduced the loss of slope-based estimated GFR
by 1.19ml/min/1.73m2 (95% CI, 0.31, 2.69) which




Not only do we challenge the interpretation of Casas
et al. [1] concerning the benefit from treatment with
ACEIs/ARBs at the primary and secondary renal
endpoints in their meta-analysis. We also doubt
whether their assertion [1], that BP lowering per se is
renoprotective, is borne out by the data they reported.
They found across the three strata of mean change
in systolic BP attained in the trials (6.9, 1.6 and
1.5mmHg) a statistically significant and clinically
important renoprotective benefit of ACEIs/ARBs:
reduction of ESRD by 26 and 23%, respectively,
in the first two strata and a non-significant reduction
by 10% in the third. These observations are more
consistent with an ACEIs/ARBs benefit that is fairly
uniform over a broad range of mean BP change and
are consistent with two recent large controlled trials
[6,7] with different levels of target BP which do not
support the assumption of Casas et al. [1], yet the
AASK trial (African American study of kidney
disease) supports the notion of renoprotection by
ACEI [6].
The ALLHAT trap
It is important to note that Casas et al.’s [1] selection
of trials may have been biased by the failure to fully
consider the implications of inclusion and exclusion
criteria in the selection of studies for their meta-
analysis. Thus they end up with a very heterogeneous
selection of trials. For example, as discussed in detail
subsequently, inclusion of a single investigation, the
ALLHAT study, profoundly influenced the summary
measures of effect in the meta-analysis. ALLHAT [8]
was the largest clinical trial of hypertension therapy
ever conducted in the US. We emphasize that
ALLHAT was not designed as a renal endpoint
study and crucial renal data were not collected.
The participants were randomly assigned to one of
the three active treatment arms: chlorthalidone,
amlodipine and lisinopril. ALLHAT exclusion criteria
included heart failure, a serum creatinine in excess of
176.8 mmol/l and current treatment with an ACEI for
underlying kidney disease (!). The net effect of these
exclusion criteria may have been to create a cohort
of individuals that was of considerably lower risk for
renal outcomes, when compared with trials specifically
designed to assess the reno-protective benefits of
ACEIs and ARBs. In addition, the low renal risk of
patients of the ALLHAT trial was very poorly defined.
ALLHAT included about 12 000 hypertensive diabetic
patients, for whom no information on urinary albumin
or retinopathy was available [8], contrary to any
diabetes guideline. As acknowledged by Rahman
et al. [8] in the analysis of renal findings from
ALLHAT but not in the meta-analysis of Casas et al.
[1], presumably few patients with diabetic nephropathy
were included in the ALLHAT trial. Recruitment
for ALLHAT started 2 years after the publication
of the landmark trial in diabetic nephropathy [9],
which demonstrated the efficacy of ACEIs in diabetic
nephropathy—an indication for ACE inhibition
was an exclusion criteria for ALLHAT, however.
The beneficial renal effect of RAS blockade is seen
preferentially in patients with higher degrees of
proteinuria [2]. In several trials, the effect of RAS
blockade on proteinuria (and probably on progression)
was enhanced by a negative sodium balance
and abrogated by a high sodium intake [10].
In ALLHAT, diuretics were forbidden by protocol
in the lisinopril-treated group, certainly leading to
an underestimate of the renal benefits of ACE
inhibition.
ACEI/ARB not indicated in
diabetic nephropathy?
A further issue that must be raised is the claim by
Casas et al. [1] that inhibition of the RAS is ineffective
in diabetic nephropathy. Three large randomized
controlled trials in patients with type 1 or type 2
diabetes and overt nephropathy [9,11,12] document
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a substantial and significant reduction of progression
with ACEIs or ARBs as compared with alternative
antihypertensive agents achieving virtually identical
BP control. These individual clinical trials have been
complemented by a recent meta-analysis on primary
prevention of overt diabetic nephropathy [5]. Included
were 16 trials with 7603 patients that compared ACEIs
with placebo, a calcium channel blocker (CCB),
combined ACEIs and CCB or other antihypertensive
therapy. Compared with placebo, ACEIs significantly
reduced the development of microalbuminuria
(RR 0.60; 95% CI 0.43–0.84) and tended to have
a protective, but statistically marginal benefit for
doubling of creatinine (RR 0.81; 95% CI 0.24–2.71)
and all-cause mortality (RR 0.81; 95% CI 0.64–1.03).
Compared with a CCB, ACEIs significantly prevented
the development of microalbuminuria (RR 0.58;
95% CI 0.40–0.84).
Casas et al. [1] ignore most of these trials [5] and
lump data from a smaller number of carefully defined
patients (about 3500) together with data from the
12 000 people of the inadequately cared for patients
in ALLHAT. We strongly suspect that in their sub-
analysis on diabetes, Casas et al. [1] aggregated
patients with diabetic nephropathy and diabetic
patients with hypertensive nephropathy—obviously
two different diseases [13]. The vast number of patients
in the latter group from the ALLHAT trial [8]—in
which no difference in renal outcomes was found
between lisinopril and chlorthalidone, despite lower
BP in the latter group—may have overridden the valid
data in patients with true diabetic nephropathy which
had documented a BP-independent effect of RAS
blockade on progression [4,5]. Carefully designed
trials [4,5,9,11,12] prompted guideline committees
to declare ACEIs/ARBs as the first line treatment
in patients with diabetic nephropathy. If—as we
suspect—the conclusion of Casas et al. [1] is wrong
(. . . ‘little justification for ACEI/ARB to be first-line
choices for renoprotection in diabetes . . .’), numerous
patients with diabetic nephropathy may be seriously
at risk and harmed.
Comparison of Casas et al. with
previous meta-analyses
How does the meta-analysis of Casas et al. [1]—which
includes the ALLHAT trial that was not designed
to be a trial on renal disease and lacks crucial
information—compare with some preceding meta-
analyses? Jafar et al. [2,3] published two meta-analyses
of 11 trials addressing the effect of ACEIs vs active
control or placebo on progression in non-diabetic
renal disease. These authors used the much more valid
approach in analysing individual patient data rather
than restricting the analysis to the use of a published
mean data, as did Casas et al. [1]. Jafar et al. [2,3]
could thus appropriately adjust for confounding
factors. The individual data bases the analysis
of Jafar et al. [2,3] on much firmer grounds than
that of Casas et al. [1] and the results thus obtained
have clinically important ramifications. ACEIs
reduced the risk of progression (assessed as doubling
of serum creatinine or ESRD) by 33% (95% CI 47–16)
even when adjusted for BP and for several other
confounders [2,3]. There was also no interaction
term for current systolic BP and ACE inhibition. The
latter may seem surprising. However, in placebo-
controlled trials all patients received open-label anti-
hypertensives (except ACEIs) to reach goal BP. In fact,
the RR for progression only increased with higher
on-treatment systolic BP in the presence of proteinuria;
there was no relationship of progression to BP at low
pressure levels.
No data—Proteinuria, the hallmark of renal risk
Jafar et al. [2,3] point out that the magnitude of the
BP-independent renoprotection by ACEIs increased
dramatically with increasing rates of proteinuria—an
important confounder on which no information,
whatsoever, is provided in the meta-analysis of Casas
et al. [1]. This lack of information is the more
deplorable since recent data strongly suggest that
proteinuria and its reduction by therapy is pivotal
when analysing the progression of renal diseases [14].
Casas et al. [1] do not even discuss the issue of
proteinuria—an omission that renders this analysis
virtually useless for nephrologists. What made the
authors fall silent on this crucial point? Their conclu-
sions [1] are almost totally based on the ALLHAT
trial which provides roughly 90% of the data and
in which quantitative data on proteinuria were not
obtained—an irritating limitation even for a trial
planned 10 years ago, since proteinuria is an important
determinant of cardiovascular and renal risk. The
publication of Rahman et al. [8] acknowledges that
the subpopulation of patients in ALLHAT with renal
disease presumably concerned mainly those with
ischaemic renal disease—in which nephrologists
would not expect an overwhelming renoprotective
effect of ACEIs to begin with [2,3]. As a logical
consequence, the authors of the ALLHAT trial state
[8] that their findings by no means refute guidelines
that recommend inhibition of the RAS in patients with
diabetic or proteinuric nephropathies. This balanced
statement contrasts with the blunt recommendation
of Casas et al. [1] not to use ACEIs/ARBs as first
line treatment in renal disease. Astonishingly the latter
statement is based almost exclusively on the same
ALLHAT data.
Lack of patient-level data
Unfortunately there are numerous further methodo-
logical limitations in Casas et al.’s [1] data. A meta-
analysis on study level rather than on the level of
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individual patient data is much more restricted in
drawing valid conclusions on the effect of addi-
tional patient characteristics on study outcome.
Relationships of any parameter with patient averages
across trials may not be the same as relationships for
patients within trials. There is a high risk for spurious
relationships caused by so-called ‘ecological fallacy’,
which can only be investigated with individual patient
data [2,3]. The latter problem is specifically noteworthy
for BP. Their meta-regression analysis on BP and
renal outcomes relates the mean change of BP within
tertiles to ESRD occurrence [1]. There is no guarantee
that tertiles of mean BP within the studies reflect the
relationship of individual BP with renal outcome.
In addition, the authors [1] did not have information to
adjust for important patient-related factors such as
individual BP, age, gender, smoking, body weight
and other factors that are related to renal outcomes.
Finally, the meta-analysis [1] did not consider
further important studies that are independent of
changes in BP. RAS inhibition slowed down the
progression even in advanced renal insufficiency [15]
and failed to consider information that the degree of
renoprotection depends on the intensity of RAS
blockade [16].
Conclusions
Should we trust the meta-analysis of Casas et al. [1]
or the guidelines of professional societies? Should we
treat a diabetic patient with a proteinuria of 2 g/day
without ACEIs or ARBs? Since the conclusion of the
meta-analysis [1] is based on a very large, but for the
purpose of renal outcomes, sub-optimally designed
trial [8] which contradicts the bulk of much better
designed trials [2–5], we are certain that the recom-
mendation to use ACEIs/ARBs as first-line therapy in
patients with proteinuric renal disease will stand the
test of time. We add that the issue may be largely
academic, since most patients with renal disease need
several antihypertensive drugs anyway, to achieve
target BP [17].
It is not a pleasant task to expose the shortcomings
in other authors’ works, but our conviction that
the optimal treatment of our patients—specifically
proteinuric patients—is at stake, overcame this
inhibition and made us speak out for what we feel is
the best proven treatment for our patients.
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